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Diabetic foot adalah salah satu daripada komplikasi akibat penyakit diabetes mellitus 
yang teruk. Kos perawatan penyakit ini semakin meningkat disebabkan oleh peningkatan 
di dalam kadar prevelennya. Dari itu, kajian ini dijalankan dengan tujuan untuk 
menganggarkan kos yang ditanggung oleh pemberi khidmat jagaan kesihatan dalam 
merawat diabetic foot dan menentukan faktor-faktor berkaitan dengan kos tersebut. 
KAEDAH KAJIAN: 
Satu kaj ian kos penyakit telah dilakukan secara prospektif terhadap 1 0 1 pesakit diabetic 
foot yang dimasukkan ke Wad Ortopedik 4 Utara dan 4 Selatan, Hospital Universiti 
Sains Malaysia, Kota Bharu, Kelantan daripada I hb Mei hingga 31 hb Disember 2005. 
Subjek telah ditemuramah dan rekod perubatan mereka telah diteliti. Penentuan kos 
secara mikro dan makro telah dilakukan ke atas setiap pesakit. Kos keseluruhan 
perawatan diabetic foot dibahagikan kepada kos kapital dan kos ulangan. Purata kos per 
pesakit per kemasukan telah dikira. Analisis multiple linear regression digunakan untuk 
menentukan faktor sosio-demografi dan faktor klinikal yang mempengaruhi kos 
perawatan diabetic foot. 
KEPUTUSAN: 
Majoriti subjek adalah Melayu (97.1 %) dan selebihnya adalah Cina. Pesakit perempuan 
(51.5 %) melebihi lelaki (48.5 %). Purata (SD) untuk umur (tahun) subjek, lama masa 
mengidap diabetes mellitus (tahun) dan tempoh masa diwadkan (hari) adalah 56.2 (9. 78), 
10.7 (6.41) dan 13.2 (4.68), masing-masing. Purata (SD) kos keseluruhan merawat 
XV 
diabetic foot per pesakit per kemasukan wad adalah Ringgit Malaysia (RM) 11,763.88 
(6,843.96). Purata (SD) kos kapital dan ulangan adalah RM 53.51(32.83) dan 
RM11,710.37 (6,813.24) masing-masing. Analisis multiple linear regression mendapati 
bahawa amputasi, cuci luka, kewujudan demam semasa diperiksa, kewujudan hipertensi 
dan penampalan kulit adalah faktor yang signifikan mempengaruhi kos. 
KESIMPULAN: 
Purata kos rawatan diabetic foot per pesakit per kemasukan wad ialah RM 11,763.88, 
yang kebanyakkannya disumbang oleh kos ulangan serta berkaitan dengan penyakit 
hipertensi, pesakit demam semasa diperiksa, dan jenis pembedahan yang dilakukan 
samada penampalan kulit, amputasi atau cuci luka. Dari itu, langkah-langkah pencegahan 
diabetic foot dan keterukkannya perlu diperhebatkan serta peningkatan kualiti 
pengurusan penyakit diabetes mellitus dan komplikasinya yang kronik dapat 
mengurangkan tempoh berada di wad serta beban ekonomi. 
Kata kunci: diabetic foot; kos pemberi khidmat jagaan kesihatan; kos kapital; kos 




Diabetic foot is one of the devastating complications of diabetes mellitus. The cost of 
treating it is increasing as its prevalence is increased. Therefore, the aim of this study 
was to estimate the direct cost incurred by health care provider in treating diabetic foot 
and its associated factors in the Orthopaedic Wards, Hospital Universiti Sains Malaysia 
(HUSM), Kota Bharu, Kelantan. 
METHOD: 
A cost of illness study was done prospectively whereby 1 01 diabetic foot patients who 
were admitted to the Orthopaedic wards 4 Utara and 4 Selatan, HUSM from 1st May to 
31st December 2005 were purposely selected. The subjects underwent face-to-face 
interview and their medical records were reviewed. The macrocosting and microcosting 
were performed on each of the patient. The cost of treating diabetic foot was divided into 
capital and recurrent costs. The mean cost per patient per admission was calculated. 
Multiple linear regression analysis was used in determining the socio-demographic and 
clinical characteristic factors associated with the cost. 
RESULT: 
Majority of the subjects were Malay (97.1 %) and the others were Chinese. Female 
(51.5%) was predominant than male (48.5%). The mean (SD) age (years) of the subjects, 
duration of having diabetes (years) and length of hospitalization (days) was 56.2(9.78), 
10.7(6.41) andl3.2 (4.68), respectively. The mean (SD) direct cost per patient per 
admission was Ringgit Malaysia (RM) 11,763.88 (6,843.96). The mean (SD) for capital 
.. 
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and recurrent cost was RM 53.51(32.83) and RM11,710.37 (6,813.24) respectively. 
Amputation, debridement, fever at presentation, presence of hypertension and attendance 
of split skin grafting were significantly associated with the cost by multiple linear 
regression analysis. 
CONCLUSION: 
The mean direct cost per patient per admission of treating diabetic foot was RM 
11,763.88, which mostly contributed by recurrent cost and was associated with the 
presence of hypertension as co-morbidity, patient who presented with fever and surgical 
procedure performed which was split skin grafting, amputation or debridement. Hence, 
strategies in preventing the lesion and its severity need to be strengthened and 
improvement in the management of diabetes mellitus and its chronic complications can 
reduce the length of hospitalization and its economic burden. 
Key words: diabetic foot; health care provider's cost; capital cost; recurrent cost; 
associated factor 
xviii 
CHAPTER ONE: INTRODUCTION AND LITERATURE 
REVIEW 
1.1 Diabetes: A Global Problem 
Diabetes Mellitus is a common disease worldwide with an estimated 124 million 
people had diabetes in 1997, and rising up to 177 million in 2000. By the year 2010, the 
numbers will be increased to at least 221 million (Zimmet et al., 1997). World Health 
Organization (WHO) expects the numbers of adults (aged 20 and above) with Diabetes to 
rise to 300 millions by year 2025 (120% increment in 30 years). Furthermore, 80% of those 
individual will be found in developing countries by the year 2025 (WHO, 1997). The top 
three countries in the world with Diabetes were in the following order: India, China and 
USA (Bjork, 200 I). In USA, diabetes affects 3% to 6% of the population, or between 8 and 
16 million people, and half of these people have undiagnosed diabetes (Holzer et al., 1998). 
In Malaysia, prevalence of diabetes has steadily increased over the years with an estimate of 
0.65% in 1960 to 2% in 1982, 6.3% in 1985 and 8.3% in 1996 (NHMS, 1996). 
Long standing Diabetes Mellitus was associated with an increase prevalence of both 
macro and micro vascular complications. United Kingdom Prospective Diabetes study 
(UKPDS), 1977-1991 has revealed that 50% of patient with Type 2 Diabetes had 
complication by the time they were diagnosed and 30% had serious complication 9 years 
after been diagnosed. On average, people with diabetes were three times more likely to be 
hospitalized than people without diabetes. The risk of premature death was higher for 
individuals with diabetes compare to the non-diabetic, and the life expectancy was I 0 - 15 
times shorter (Bjork, 2001 ). 
According to Malaysian Diabetes Care Data Project, ( 1998), the proportion of 
diabetic complications in Malaysia were 61% for nephropathy, 58% for neuropathy, 53% for 
retinopathy, 9% for myocardial infarct, 6% for stroke, 3% for diabetic foot, 2% for 
amputation, and 1% for renal failure. According to the annual report by Malaysia's Ministry 
of Health, (2004), the total numbers of new cases of Diabetes Mellitus in the year 2004 were 
26, 953 in which 70% (18,838) had no complication during diagnosis and 30% (8,115) had 
complications at the time of diagnosis. Out of the 30% who had the complications, it's been 
microalbuminuria (35%), nephropathy (24%), neuropathy (21%), retinopathy (10%) and 
foot ulcer (I 0%). 
1.2 Lower Extremity Ulcers: The Devastating Complication 
Lower extremity ulcers (LEU) are the most common cause of hospitalizations, 
morbidity and mortality in people with diabetes (Moulik et al., 2003; Acker et al., 2000; 
Curry et al., I 998 and Holzer et al., 1998). LEU is a serious complication for people with 
diabetes and a significant economic burden for both patients and health care providers. In 
USA, the incidence of diabetic foot ulcers was 2 % per year (Ramsey et al., 1999). In one 
British study of a large cohort of neuropathic patients, there was a 7% one year incidence of 
first foot ulcer. Although many of these ulcers were superficial and heal with standard 
treatment, up to 15% of people with diabetes will develop a chronic non-healing ulcer over 
2 
their lifetime (Holzer et al., 1998). In Malaysia the prevalence of diabetic foot ulcer was 6 % 
(MOH, 2003). It shows a double increment from 3 % in the year 1998. 
Diabetic foot is resulted from both macro and micro vascular complications. Diabetic 
peripheral neuropathies result in abnormal pressure being applied to the foot which diabetic 
ischaemia put the foot even at higher risk (Jeffcoate et al., 2003). The severity of diabetic 
foot can be determined by applying classification system proposed by Wagner (Lavery et 
al., 1996). Wagner's system classifies foot ulcers into 5 stages according to depth and 
penetration of the wound, extent of infection and tissue necrosis as shown in Table 1.1. 









Pre ulcer state, healed ulcer and/or presence of deformity 
Superficial ulcer without involvement of the subcutaneous tissue 
Deep ulcer involving subcutaneous tissue like tendon, ligament or joint 
capsule 
Present of osteomyelitis 
Gangrene of the forefoot 
Gangrene of the entire foot 
Source: Lavery et al., ( 1996). 
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1.3 Costing of Diabetic Foot 
Cost is defined as the value of resources used to produce an output, including a 
specific health service or a set of services (Creese and Parker, 1994). 
1.3.1 Classification of Costs 
Classification of cost is very important in calculating the costs of treating disease. In 
this study, the classification of cost by inputs was used (Creese and Parker, 1994): 
I. Capital costs 
a. Vehicles: bicycles, motorcycles, four-wheel-drive vehicles. 
b. Equipment: refrigerators, other equipment with a unit cost of RM 500 or 
more. 
c. Buildings: health centres, hospital, storage facilities. 
d. Training, non-recurrent: training activities for health care personel that 
occur only once or rarely. 
e. Social mobilization, non-recurrent: promotion, publicity campa~gns, 
which occur once or rarely. 
2. Recurrent costs 
a. Personnel (all types): supervisors, health workers, technicians, 
consultants, doctors, staffnurse. 
b. Supplies: drugs, vaccines, materials use for wound dressings, small 
4 
equipments (unit cost of less than RMSOO). 
c. Vehicles, operation and maintenance: petrol, tyres, spare parts 
d. Buildings, operation and maintenance: electricity, water, cleaning, repairs 
to electrical supplies, telephone. 
e. Training, recurrent (short in-service courses) 
f. Social mobilization: operating costs, other operating costs not included 
above. 
Capital costs are defined as cost of items (asset) with a life more than one year like 
building, equipment and vehicles. Recurrent costs are cost that are necessarily incurred each 
year like salaries, drugs, electricity, water and spare parts (Creese and Parker, 1994). 
1.3.2 Method of Costing 
The economic consequences of the diabetes and its complication can be calculated 
either by direct costs or direct costs plus indirect costs and societal costs. The direct costs are 
calculated on the basis of the number of physician visit, medicines used, laboratory and 
radiological used and transportation costs paid. It's mainly borne by health care providers. 
The indirect costs represent the costs to the society due to the morbidity and premature 
mortality; the cost is calculated on the basis of sick-leave days, employment situation, 
income and family home care. These costs are generally borne by the patients and their 
families (Bjork, 2001). The societal costs are the costs related to psychosocial aspect of the 
illness and its effect on the patient's quality of life such as pain, disability accounted and 
5 
depression. These types of costs are rarely calculated due to the difficulty in measuring it 
(Zhang et al., 2004). 
Cost of illness study can be done either prospectively or retrospectively, top-down or 
bottom-up approaches or prevalence and incidence-based (Tarricone, 2005). Ragnarson and 
Apelqvist, (1997), did a study on long-term costs for foot ulcers in diabetic patients in a 
multidisciplinary setting. Patients were treated and followed prospectively by a foot care 
team. A retrospective economic analysis was performed on costs for 274 patients during 3 
years from healing of an initial foot ulcer, with or without amputation. Costs were estimated 
for inpatient care, outpatient care, home care, and social service. The cost calculations 
include costs due to complications and disability related to the initial ulcer, costs related to 
recurrence of ulcer, and costs for prevention of new ulcers. The data collected in this study 
were secondary data. Therefore the accuracy of the cost was dependent on the accurateness 
of the data. 
Tennvall et al., (2000) also did a cost of illness study prospectively. In this study, a 
multidisciplinary team followed the patients from admission until final outcome, i.e. primary 
healing or healing with amputation or death. Data from both the prospectively collected 
patient material and from patient records were used to estimate the cost for hospital care, 
antibiotics, surgery, out-patient care, staff attendance, drugs and material for ulcer dressings, 
and orthopedics appliances. The result of this study is more reliable compare to the study by 
Apelqvist, ( 1997) as the data was collected prospectively. However, the study is more time 
6 
consuming and difficult to do logistically as the researcher has to follow the subjects till the 
study period end. 
The cost of illness analysis also can be done by top-down or bottom-up approaches. 
In top-down approach, it's involved in allocating total national healthcare expenditures by 
type of care (i.e. hospital care, primary care, physicians, services etc) to each of disease 
category. Amrizal, (2000) did a study on cost of treating diabetes, neonatal jaundice and pre-
eclampsia in Hospital Universiti Sains Malaysia (HUSM) by using the top-down approach. 
He used the expenditure by HUSM and divided it to the total numbers admission of 
diabetes, neonatal jaundice and pre-eclampsia. As in bottom-up approach, the estimations of 
costs involved 2 steps. The first step is to estimate the quantity of health resources used and 
the second step is to estimate the unit cost of each of the health resources used. The costs are 
then calculated by multiplying unit costs by the quantities (Tarricone, 2005). There were not 
many studies using bottom-up approach, as even it is more accurate than top-down 
approach, but it was more time consuming and logistically heavier. 
Cost of illness (COl) analysis can be done according prevalence or incidence-based. 
In prevalence-based COl, the annual cost was estimated using all cases that existed in that 
year, whereas for incidence-based study cost was estimated using the new cases that arise 
for the defined period (Tarricone, 2005). 
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1.3.3 Economic Burden of Diabetic Foot 
Diabetic foot is one of the costly complications of diabetes. The total costs of 
treating a diabetic foot ulcer per episode range from US Dollar $10,000.00 (RM 38,000.00) 
to nearly $60,000.00 (RM 228,000.00), depending on ulcer severity and clinical outcome 
(Holzer et al., 1998). One report estimates 800,000 prevalent ulcer cases in the United States 
with costs averaging US$5,457.00 (RM 20,736.60) per year per patient or total national 
annual costs ofUS$5 billion (Frykberg, 2000). 
In Sweden, the estimated total cost per patient during 3 years of observation was 
US$26,700.00 (RM 101,460.00) for primary healed patients with critical ischemia and 
US$16, I 00.00 (RM 61, 180.00) for primary healed patients without critical ischemia. For 
patients who healed with an amputation, the costs were US$43,1 00.00 (RM 163, 780.00) 
after a minor amputation and US$63,100.00 (RM 239,780.00) after a major amputation 
(Ragnarson-Tennvall and Apelqvist, 1997). A pharmacoeconomic study in France, in 2003 
using direct and indirect costs put average monthly cost in the outpatient management for 
diabetic foot at 697.00 Euros (RM 3,275.90), short hospital stays at 1556.20 Euros (RM 
7,3 14.14) and 34.76 Euros (RM 163.37) for sick leaves (Girod, et al., 2003). 
A study conducted by Holzer et al., (1998) in United State of America (USA) found 
that the total cost of treating diabetic foot per episode for Wagner's stage I or 2, stage 3 and 
stage 4 or 5 is US$1,929.00 (RM 7,330.20), US$3,980.00 (RM 15,124.00) and 
US$15,792.00 (RM 60,009.60) respectively. Total expenditures (2 years) were 
US$16, I 92,780.00 (RM 61 ,532,564.00) with average annual cost per patient was 
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US$2,687 .00 (RM 10,21 0.60). There was significant increase in costs as the severity level 
increased. Medicare expenditures in USA for lower extremity ulcers patients were on 
average 3 times higher than those for Medicare patients in general (US$15,309 versus US$ 
5,226). Patients with lower extremity ulcer related in-patient use had the most expensive 
claims (US$ 14,641 ), followed by patients with osteomyelitis (US$ 8,942) and patients with 
debridement (US$ 5,064) (Harrington et al., 2000). This study showed that in-patient 
management did influence the cost, so as the severity of the illness. 
In Malaysia, diabetic foot is also a major source of morbidity, a leading cause of 
hospital bed occupancy and account for substantial health care resources. It accounts for 12 
% of all diabetic hospital admissions for the government hospitals (MOH, 2003). On the 
average and depending on location and type of private facility, a 5-day stay for mild to 
moderate diabetic foot problems will cost approximately Ringgit Malaysia (RM) 2500 to 
3500, whereas a 7-day stay for more severe cases will cost around Ringgit Malaysia (RM) 
7000 to 8000 (MOH, 2004). 
There was no published study on cost of treating diabetic foot ulcer being done in 
government health facilities. However, Nabilla et al., (2003) did a cost of illness analysis on 
direct cost of treating diabetes in an outpatient setting in Malaysia. The objective of the 
study was to determine the provider's cost (cost borne by MOH) and patients' cost. The 
costing was done using the top-down approach. Direct costs incurred by provider were 
gleaned from available record in the year 2002 and costs incurred by patients were 
determined by conducting a survey of 253 diabetics visiting an outpatient clinics using 
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questionnaire from 23rd October to 1 stNovember 2002. It was discovered that provider's cost 
per diabetic patient per year was RM 185.97, patient's direct cost per year was RM 55.23 
and total direct cost per diabetic patient per year was RM 241.19. In their study, Nabilla, et 
al (2003) calculated the cost for two months duration only. She was then extrapolated the 
results to a year cost by multiplying the results with 6 months. Hence the results may be 
underestimated. 
1.4 Factors Associated With the Cost of Treating Diabetic Foot 
There were several factors associated with the cost of treating diabetic foot. These 
factors can be the socio-demographic factors of the patient or the disease characteristics 
itself. Frykberg, (2000) found among the significant associated factors of direct and indirect 
costs of lower extremity ulcer (LEU) were ulcer severity, length of admission, or present of 
co-morbidity and the cost was ranged from US Dollar $20,000 to $40,000. 
Severity of the diabetic foot influences the cost, where the cost increases with the 
level of the Wagner's classification (Holzer et al., 1998 and Acker et al., 2000). Acker et al., 
(2000), did a study on cost of treating diabetic foot in Belgium. It's was a cross-sectional 
study involving 151 diabetic foot patients from all over Belgium. The cost to the Belgium's 
National Health Care per diabetic foot patient for Wagner stage 0, 1, 2, 3, 4 and 5 were US$ 
698, US$ 1,378, US$ 10,569, US$ 19,676, US$ 19,174 and US$ 47,365 respectively (Acker 
et al., 2000). It showed the parallel increase in the cost as the severity of diabetic foot 
increase. 
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The longer the duration of a diabetic foot patient was admitted, the higher the cost of 
treating it. This was showed by Benotmane et al., (2001) in Algeria, where the average 
length of hospitalization was 26.87 days, 48.25 days and 65.44 days for diabetic foot grade 
l, 2 and 3 respectively (Grade I was Wagner stage 1 and 2, Grade 2 was Wagner stage 3 and 
Grade 3 was Wagner stage 4 and 5). The average cost per patient/year for treating diabetic 
foot was US$ 3,326.76, US$ 5,712.24 and US$ 7,399.74 for grade 1, 2 and 3, respectively. 
The length of hospitalization was increase as the severity increase, so as the cost of treating 
it. 
Guo et a/., ( 1998) in his study in United State found that patient's co-morbidities, 
type of diabetes mellitus, renal dysfunction, number of physicians visited, age, being male 
and living in an urban areas were associated with higher direct cost of treating diabetic foot 
ulcers. 
In Malaysia, there was no study being done on factors associated with cost of 
treating diabetic foot. However, Rohaizat et al., (2005) did a study on factors associated 
with the cost of treating orthopaedic cases in Hospital Universiti Kebangsaan Malaysia 
(HUKM), Malaysia (diabetic foot is one of the orthopaedic case). He found that among the 
factors influenced the treatment cost of orthopaedic cases were length of stay, age, female 
sex, medical partition and severity of the illness. This study was part ofthe case-mix system 
and using the top-down approach. Therefore the treatment cost calculated not accurate as it's 
may misallocate the resources used. 
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Another study by Amrizal et al., (2005) in HUKM, estimated the cost of treating 
cardiology cases and its associated factors. He used the same methodology as Rohaizat et 
al., (2005). The mean (SO) cost of surgical cardiology cases per length of stay was RM 
6,530 (4,588). He found that there were six factors were significantly influenced the cost i.e. 
length of stay, age, medical partition, discharge died, severity level 2 and severity level 3. 
Amrizal, (2000) too did a study on cost of treating diabetes mellitus in Medical Wards, 
Hospital Universiti Sains Malaysia (HUSM). He found that among the significant factors 
that influenced the cost was length of stay, co-morbidity and numbers of laboratory and 
radiological investigations done. 
From few studies mentioned above it was found that among the significant factors 
which were associated with the cost of treating disease were age, male sex, area of living, 
length of hospitalization, disease severity and presence of co-morbidities. 
1.5 Rationale of The Study 
Unfortunately, there were no studies on costing of treating diabetic foot being done 
m Malaysia. Therefore, this study is aimed to provide the estimate of cost of treating 
diabetic foot per admission in HUSM. So that this information can be used by health care 
providers and policy makers as a guiding in determining budgetary allocations, prioritizing 
research funding, justifying funding for existing and new disease programmes. Cost of 
illness estimates can also be used by government as a measure of disease burden in term of 
economic burden. This study provides valuable data for informing and educating policy 
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makers about how many health care resources are consumed in managing certain diseases. It 
may provide an evidence that the cost of treating diabetic complications like diabetic foot is 
high (Holzer eta/., 1998), therefore preventive programmes such as a multidisciplinary team 
in managing diabetic foot would be given higher priority in health policy plans. 
1.6 Conceptual Framework 
All of the diabetic foot patients who were admitted to the Orthopaedic Wards HUSM 
were selected, based on inclusion and exclusion criteria set by the researcher. Wards staff 
managed these patients accordingly till they were discharged and underwent operation if 
indicated (Figure 1.1 ). Each patient was different in his or her clinical characteristics such as 
severity of diabetic foot; which can influence the total health care costs. 
Cost of treating the diabetic foot as in-patient involving the cost of the health care 
provider, patient and their families. This study only focused on cost incurred by provider of 
the services. Health care provider cost included the capital and recurrent cost, with the 
building and equipment costs were sub-grouped into capital cost and salary, operation and 
maintenance, laboratory investigation, radiological investigation, drug, surgical, supplies 
and dressing cost were put in the recurrent cost (Figure 1.2). 
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Patient was admitted to Wards 4 Utara I 4 Selatan HUSM I 






History taking and physical examination by medical officer 
I). Further management as ordered by medical officer: 
-HO -blood, wound sample taking 
-MO-laboratory and radiological investigation 
-vascular investigation 
-medical treatment of co-morbidities 
-SN -antibiotics treatment 
- wound care/dressing 
-surgical procedure- debridement/Toe 
amputation/B KA/ AKA/SSG 
-blood sugar monitoring and control 
2). Reassessment by medical officer/specialist 
Discharge: 
-discharged home 
-at own risk discharge 
-transfer to other hospital/wards 
-died 
Figure 1.1 Flow Chart of Diabetic Foot Management in Orthopaedic Wards, HUSM 
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Health Care Providers Diabetic Foot Patients 
Health Services Provided 
-Early detection & control of diabetes 
mellitus in community 
-Prevention of diabetic foot 
-Diabetic education among diabetics 
-Employment of manpower expert in 
diabetic foot care rather than more 
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CHAPTER TWO: RESEARCH QUESTIONS AND 
OBJECTIVES 
2.1 Research Questions 
1. What is the direct cost of treating diabetic foot per patient per admission in 
Hospital Universiti Sains Malaysia (HUSM)? 
2. What are the factors associated with the direct cost of treating diabetic foot in 
HUSM? 
2.2 Objectives 
2.2.1 General Objective 
This study attempts to perform costing on diabetic foot management in HUSM. 
2.2.2 Specific Objectives 
1. To estimate the direct cost per patient per admission of treating diabetic foot 
in HUSM. 
2. To determine the factors associated with the direct cost of treating diabetic 
foot patients in HUSM. 
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CHAPTER THREE: METHODOLOGY 
3.1 Study Area 
The study was conducted in Orthopedic wards (4 Utara and 4 Selatan Wards), 
Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian, Kota Bharu, Kelantan from I st 
May 2005 till 31st December 2005. HUSM is one of the tertiary hospitals in Kelantan that 
accepts referral from all other district hospitals in Kelantan and also Besut Hospital, 
Terengganu. It renders both secondary and tertiary medical care to the 468,936 residents of 
Kota Bharu (Statistics, 2003). 
3.2 Study Design 
This study is a cost of illness analysis. It is a prospective study and partial economic 
evaluation since it only measures the costs but not the outcomes of the study (Drummond et 
al., 1997). 
3.3 Population and Sample 
3.3.1 Reference population 
All diabetic foot patients at HUSM from 1st May to 31st December 2005 
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3.3.2 Source population 
All diabetic foot patients who were admitted to the Orthopaedic wards, HUSM from 
1st May through 31st December 2005. 
3.3.3 Inclusion and Exclusion Criteria 
Inclusion Criteria: 
1. All diabetic foot patients who were admitted to the Orthopaedic Wards 
HUSM from I st May to 31st December 2005. 
2. Type 2 Diabetes Mellitus patients only 
Exclusion Criteria: 
I. Subsequent admission of the same patient within the study period. 
2. Stage 0 (pre ulcer) diabetic foot according to Wagner's Classification. 
3. Comatosed diabetic patients. 
4. Subject who were diagnosed to have diabetes mellitus after the admission. 
This because duration of having diabetes is one of the studied associated 
factors. 
5. Diabetics with renal failure on dialysis. 
3.3.4 Sampling Method 
Review of HUSM's record and hospital admission and discharges revealed that the 
numbers of diabetic foot patients admitted to the Orthopaedics wards were 135 for the year 
2002, 166 for the year 2003 and 179 in the year 2004. Because of the limited numbers of 
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subject, non probability sampling was done in this study. Consecutive recruitment of eligible 
subjects was employed. Patients who fulfilled the inclusion and exclusion criteria were 
recruited until the desired number was obtained. In recruiting the subjects, effort was made 
to make sure that sex distribution was balanced. Approximately at the end of the recruitment 
period (31st December 2005), we were able to recruit 49 male and 52 female diabetic foot 
patients. 
3.3.5 Sample Size Calculation 
The calculation of the sample size (n) was done for all objectives studied. However, 
only the one that yielded the biggest sample size was selected to determine required sample 
size. For the objective number 1 (i.e. To estimate the costs per patient per admission of 
treating diabetic foot in HUSM), single mean formula was used to calculate the sample size. 
The formula was as below: 
n == ----------
Za.12 == 1.96 (Critical Z value for 95% confidence interval of the estimate) 
cr == RM 6000 (Standard deviation of cost of treating Orthopaedic cases per patient 
in HUKM) (Rohaizat et a!., 2005) 
!:::.. == RM 1200.00 (Precision). 
( 1.96)2 (RM 6000i 
n == ----------------------
(RM1200)2 
== 97 plus I 0% drop out== I 07 
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The sample size required for the second objective was calculated using PS Software. 
It was calculated based on the study done by Rohaizat et al., (2005) by using male sex as the 
associated factors of the cost of treating Orthopaedic cases in Hospital Universiti 
Kebangsaan Malaysia (HUKM). This study was chosen as the reference for calculating 
sample size because of it's the most similar costing study with present study being done in 
Malaysia. (Note: diabetic foot is one of the orthopaedic cases in the study). 
{l = 0.05 
Power= 80% 
/:!,. = RM 2600 (Difference in population mean) 
SO= RM 4500 (Standard deviation of the mean cost of treating Orthopaedic cases 
among male sex) (Rohaizat et al., 2005) 
n = 48 (approximate 48 male and 48 female were expected to be recruited) 
Therefore the sample size for both groups was 48 x 2 = 96 plus 10% ( 1 0) drop out= I 06. 
The sample size for the second objective was also calculated by using PS Software 
based on variable length of stay (LOS) as the associated factors of the cost of treating 
Orthopaedic cases in HUKM (Rohaizat et al., 2005). 
{l = 0.05 
Power= 0.8 
cr = RM 2530 (Standard deviation of the regression) 
cr = 9.35 (Standard deviation of the LOS) (Rohaizat et al., 2005) 
A. = 100 (RM 100.00 increase per one day of length of stay) 
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n = 60 (Its mean that we need 60 plus l 0% drop out patients with diabetic foot as our 
study subjects). 
It is expected that the number of subjects is about 120 - 140 per year, based on 
previous HUSM admissions and discharge's record, therefore sample size of 97 is sufficient 
for both objectives since there was no drop out present in this study. 
3.3.6 Research Tools 
There were 2 economic evaluation forms used to obtain the data on costing, namely: 
I. Macrocosting form (Appendix 4) 
2. Microcosting form (Appendix 5) 
Macrocosting form were used to obtain data on cost of building, list and cost of the 
equipment (more than RM 500.00) used in treating diabetic foot, operation and maintenance 
of the facility, list of the staff categories involved in managing diabetic foot patients with 
their annual salary, duration of contact between nurses and patients, doctors and patients and 
other staffs like wards attendants, sister and wards assistant and patients. The information 
gathered was for the year 2004. 
As for the microcosting form, it contained data on socio-demographic and medical 
condition of subjects and information needed to calculate the costs of drugs used, 
radiological and laboratory investigations, surgical intervention done, topical wound 
dressing and consumables used for each diabetic foot patient. The researcher interviewed 
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the selected diabetic foot patients. The information obtained from the interview included 
socio-demographic data and diabetic history. The socio-demographic data included sex, age, 
race, marital status, education level and monthly income. The diabetic history included the 
duration of diabetes, type of treatment oral hypoglycaemic agent (OHA) alone, insulin or 
combination of 01-IA and insulin and any con-current medical illness. The co-morbidities 
included were hypertension, coronary heart disease, stroke and I or chronic renal failure. 
The data on physical examination, laboratory and radiological investigations, topical 
wound dressing, surgical intervention and drug treatment such as intravenous antibiotic, 
insulin therapy and other oral drug therapy were obtained from patient medical records. 
3.4 Operational Definition 
3.4.1 Diabetic Foot 
The foot of a diabetic patient that has the potential risk of pathologic 
consequences, including infection, ulceration, and/or destruction of deep tissues associated 
with neurological abnormalities, various degrees of peripheral vascular disease, and/or 
metabolic complications of diabetes in the lower limb (WHO definition). 
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Pre-ulcer. No open lesion. May have deformities, erythematous areas of 
pressure or hyperkeratosis. 
Superficial ulcer. Disruption of skin without penetration of subcutaneous fat 
layer. 
Full thickness ulcer. Penetrates through fat to tendon or joint capsule without 
deep abscess or osteomyelitis. 
Deep ulcer with abscess, osteomyelitis or joint sepsis. It includes deep 
plantar space infections, abscesses, necrotizing fascitis and tendon sheath 
infections. 
Gangrene of a geographical portion of the foot such as toes, forefoot or heel 
Gangrene or necrosis of large portion of the foot requiring major limb 
amputation (Wagner, 1981 ). 
3.4.3 Discharge 
Any patients who were spilled out from Orthopedic wards, HUSM either was send 
back home, transferred out to the other hospital or wards or died was considered as 
discharge from Orthopedic wards and the study was terminated at that point. 
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3.4.4 Direct cost 
Direct costs of disease are those directly generated by the resources used in treating 
diabetic foot such as the number of physician visit, medicines used, laboratory and 
radiological used and transportation paid. It's mainly borne by health care providers. 
3.4.5 In-patient cost 
Costs of treating diabetic foot as in-patient in Orthopaedic wards, HUSM. It's can be 
borne by patient and health care provider. In this study researcher only concentrated on 
direct cost borne by health care provider. It was measured in Ringgit Malaysia (RM) per 
patient per admission. 
3.4.6 Health Care Provider cost 
The cost incurred by health care provider in delivering the services of treating 
diabetic foot as in patient in Orthopaedic wards, HUSM. In this study it will be the Ministry 
of Higher Education, because HUSM is one of the teaching hospitals in Malaysia. 
3.4. 7 Lifespan 
Lifespan is the estimation of the economic useful time of resources had been used in 
providing the healthcare services. In MOH and according to the standard practice by WHO, 
lifespan used for the building was 20 years and equipment (price more than RM500.00) was 
5 years (WHO, 1994). 
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